Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Mirum Pharmaceuticals
Deal Size : $445.0 million
Deal Type : Divestment
Details : Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.
Product Name : Cholbam
Product Type : Other Small Molecule
Upfront Cash : $210.0 million
July 17, 2023
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Mirum Pharmaceuticals
Deal Size : $445.0 million
Deal Type : Divestment
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Agreement
Ethypharm, CTRS Partner to Register Orphacol® in China
Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.
Product Name : Orphacol
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2020
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2011
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2010
Lead Product(s) : Cholic Acid,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
